Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Edwina Baskin-Bey"'
Autor:
Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with st
Externí odkaz:
https://doaj.org/article/4248b125094a414a9758f28ab9189376
Publikováno v:
Therapeutic Advances in Urology, Vol 6 (2014)
Prostate cancer is the second leading cause of cancer death in men and there is an urgent clinical need to improve its detection and treatment. The introduction of prostate-specific antigen (PSA) as a biomarker for prostate cancer several decades ago
Externí odkaz:
https://doaj.org/article/9e9a45b2a65a4cf48e66cb3d27af45f0
Publikováno v:
Cell Transplantation, Vol 13 (2004)
Prior studies have suggested the possibility of immune-mediated death of xenogeneic hepatocytes in a bioartificial liver (BAL) during hemoperfusion. This study was designed to elucidate how immunity may cause death of xenogeneic hepatocytes in the BA
Externí odkaz:
https://doaj.org/article/010b7557dd1946c1820a4865be4a0013
Autor:
Daniel R. Wahl, Roy E. Strowd, Theodore S. Lawrence, Corey Speers, Joel R. Eisner, Arul M. Chinnaiyan, Jann N. Sarkaria, Howard Colman, Daniel E. Spratt, Edwina Baskin-Bey, Sriram Venneti, Meredith A. Morgan, Alexander M. Hegedus, Waldemar Debinski, Tarik Bor, Carl Koschmann, Stefanie Stallard, Arvind Rao, Yangyang Yao, Weihua Zhou, Ayesha U. Kothari, Joseph Dresser, Kari Wilder-Romans, Hanshi Sun, Uchechi J. Nna, Christian K. Werner
Supplementary Figure S1: Additional expression data and comparisons of AR expression by subtype, age, sex, and common molecular alterations. Supplementary Figure S2. Tumor growth plots and mice weights for in vivo studies. Supplementary Figure S3: He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ad88dd4366195db01a6db15abda5b6
https://doi.org/10.1158/1535-7163.22521750
https://doi.org/10.1158/1535-7163.22521750
Autor:
Keith T. Schmidt, Cody J. Peer, Edwina Baskin-Bey, Joel R. Eisner, Victoria V Brown, Ravi A. Madan, William D. Figg, Jessica Kindrick
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20aa6302ae1aedea0c14c598180df7be
https://doi.org/10.1007/s00280-019-03908-0
https://doi.org/10.1007/s00280-019-03908-0
Autor:
Edwina Baskin-Bey, Tiffany A. Traina, Joel R. Eisner, Fatima Cardoso, Anthony D. Elias, Joel S. Parker, Sara R. Selitsky, Ben Ho Park, Ayca Gucalp
Publikováno v:
Breast Cancer Res Treat
Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapola
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785bd66c6531a39e846515f81c726064
https://doi.org/10.1007/s10549-018-4921-9
https://doi.org/10.1007/s10549-018-4921-9
Autor:
Jade Wulff, Paul A. Meyers, Peter M. Anderson, Edwina Baskin-Bey, AeRang Kim, Najat C. Daw, Noah Federman, Lara E. Davis, Joseph A. Ludwig, Jeffrey A. Toretsky, Ravin Ratan, James Bradley Breitmeyer, Richard F. Riedel, Margaret E. Macy
Publikováno v:
Journal of Clinical Oncology. 39:11500-11500
11500 Background: Ewing Sarcoma (ES) is a rare cancer of the young with very few treatment options in the relapsed/refractory (R/R) setting. Fusions of the EWS gene and one of five different ETS transcription factors are dominant drivers of ES. TK216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec029d7ee33f2f9596ba991bb1c77e0c
https://doi.org/10.1200/jco.2021.39.15_suppl.11500
https://doi.org/10.1200/jco.2021.39.15_suppl.11500
Autor:
Francisco Gómez Veiga, Wolfgang Warnack, Marek Salagierski, Raj Persad, Erik B. Cornel, Beatriz Lopez, Bertrand Tombal, Henri Bensadoun, Edwina Baskin-Bey, Jan Schraml, Claude Schulman, Vsevolod Matveev, Teuvo L.J. Tammela
Publikováno v:
European urology, 69 (4
Background Intermittent androgen deprivation (IAD) has received increasing attention; however, the current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative efficacy and safety benefits of IAD versus con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b06e54b5662d7412f64f5ecea3f73c25
https://doi.org/10.1016/j.eururo.2015.10.007
https://doi.org/10.1016/j.eururo.2015.10.007
Autor:
Sriram Venneti, Roy E. Strowd, Corey Speers, Stefanie Stallard, Arul Chinnayain, Hanshi Sun, Jann N. Sarkaria, Carl Koschmann, Arvind Rao, Edwina Baskin-Bey, Joseph Dresser, Christian K. Werner, Daniel E. Spratt, Meredith A. Morgan, Alexander M. Hegedus, Howard Colman, Daniel R. Wahl, Weihua Zhou, Theodore S. Lawrence, Uchechi J. Nna, Ayesha U. Kothari, Kari Wilder-Romans, Tarik Bor, Waldemar Debinski, Joel R. Eisner, Yangyang Yao
Publikováno v:
Cancer Research. 80:6267-6267
New approaches are needed to overcome intrinsic therapy resistance in glioblastoma (GBM). Because GBMs exhibit sexual dimorphism and are reported to express steroid hormone receptors, we reasoned that signaling through the androgen receptor (AR) coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad21aa0423b9436e97422febdac338e2
https://doi.org/10.1158/1538-7445.am2020-6267
https://doi.org/10.1158/1538-7445.am2020-6267
Autor:
Nicolas Jaksic, Marc Pracht, Yann Rolland, Thierry De Baere, Jerome Durand-Labrunie, France Nguyen, Jean-Pierre Bronowicki, Veronique Vendrely, Antonio Sa Cunha, Valérie Croisé-Laurent, Emmanuel Rio, Samuel Le Sourd, Patricia Said, Sebastian Freund, Edwina Baskin-Bey, Pierre Gustin, Christophe Perret, Didier Peiffert, Eric Deutsch, Enrique Chajon
Publikováno v:
Journal of Clinical Oncology. 38:537-537
537 Background: Treatment of unresectable liver cancer or liver metastases (mets) by stereotactic body radiotherapy is well tolerated but limited by the need to preserve liver function. Increasing energy deposition in the tumor while at the same time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80fe0b7037cca91fc4e67c8d9066ced7
https://doi.org/10.1200/jco.2020.38.4_suppl.537
https://doi.org/10.1200/jco.2020.38.4_suppl.537